目的 评估黄芩素在大鼠体内抑制深静脉血栓形成的活性并探索作用机制。方法 将72只雄性SD大鼠随机分为对照组、模型组、华法林（0.27 mg/kg）组与黄芩素（5、10、20 mg/kg）组。除对照组以外，每日ig给药1次，连续给药4 d。应用大鼠下腔静脉完全瘀滞血栓形成模型造模，测定各组大鼠下腔静脉内形成的血栓质量；通过HE染色病理切片观察下腔静脉的形态与静脉壁厚度；ELISA测定大鼠血浆P-选择素和白细胞介素-6（IL-6）水平，以及大鼠血小板糖蛋白IIb/IIIa含量；同时测定出血时间与凝血时间。结果 与模型组比较，黄芩素10、20 mg/kg组形成的血栓质量显著降低，下腔静脉血管壁厚度减小，血浆P-选择素水平显著降低（P＜0.05、0.01）；与模型组比较，黄芩素20 mg/kg组IL-6水平和血小板GPIIb/IIIa含量显著降低（P＜0.01）；与模型组比较，黄芩素5、10、20 mg/kg组大鼠尾出血时间显著延长（P＜0.05、0.001）。结论 黄芩素具有抑制体内深静脉血栓形成的活性，其作用机制可能与其降低体内炎症反应相关因子，以及影响血小板的功能有关。

Objective To evaluate the inhibition effect of baicalein on deep vein thrombosis in rats, and explore the mechanism. Methods 72 Male SD rats were randomly divided into the control group, model group, warfarin (0.27 mg/kg) group, and baicalein group (5, 10, 20 mg/kg). Except for the control group, each group was administered by gavage once daily for 4 days. The rat complete stasis model of inferior vena cava thrombosis was used, and the weight of thrombus formed in the inferior vena cava of each group was determined. The morphology and venous wall thickness of the inferior vena cava were observed by HE stained pathological sections. The plasma levels of P-selectin and IL-6, and the content of platelets GPIIb/IIIa in rats were determined by ELISA. Meanwhile, the rat tail bleeding time and clotting time were measured. Results Compared with the model group, baicalein 10 and 20 mg/kg group reduced the weight of thrombus formed in inferior vena cava, the thickness of the inferior vena cava vessel wall, and the P-selectin level (P< 0.05, 0.01). Compared with the model group, baicalein 20 mg/kg group reduced the IL-6 level and the content of glycoprotein IIbIIIa on platelet (P< 0.01). Compared with the model group, baicalein 5, 10, and 20 mg/kg group prolonged the bleeding time of rat tail (P< 0.05, 0.001). Conclusion Baicalein has the activity of inhibiting venous thrombosis in vivo, and its mechanism may be related to its reduction of inflammatory factors, and affecting the function of platelets.

R286.2

北京市卫生健康科技成果和适宣技术推广项目（BHTPP2022049）;首都卫生发展科研专项项目（2022-2Z-20215）